S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

OTCMKTS:GNFTF - Genfit Stock Price, Forecast & News

$16.72
-0.62 (-3.58 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$16.72
Now: $16.72
$16.72
50-Day Range
$16.64
MA: $18.78
$20.47
52-Week Range
$13.39
Now: $16.72
$26.71
Volume500 shs
Average Volume450 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNFTF
CUSIPN/A
CIKN/A
Phone33 3 20 16 40 00

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees148
Next Earnings DateN/A
OptionableNot Optionable

Receive GNFTF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFTF and its competitors with MarketBeat's FREE daily newsletter.


Genfit (OTCMKTS:GNFTF) Frequently Asked Questions

What is Genfit's stock symbol?

Genfit trades on the OTCMKTS under the ticker symbol "GNFTF."

What price target have analysts set for GNFTF?

2 equities research analysts have issued twelve-month price objectives for Genfit's shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate Genfit's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price. View Analyst Price Targets for Genfit.

What is the consensus analysts' recommendation for Genfit?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genfit.

Has Genfit been receiving favorable news coverage?

News coverage about GNFTF stock has trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genfit earned a news impact score of 2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Genfit.

Who are some of Genfit's key competitors?

What other stocks do shareholders of Genfit own?

Who are Genfit's key executives?

Genfit's management team includes the folowing people:
  • Mr. Jean-François Mouney, Co-Founder, CEO & Chairman (Age 64)
  • Ms. Nathalie Huitorel, Exec. VP, Chief Financial & Admin. Officer (Age 58)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 57)
  • Prof. Bart Staels, Co-Founder & Pres of the Scientific Advisory Board (Age 56)
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 49)

How do I buy shares of Genfit?

Shares of GNFTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Genfit's stock price today?

One share of GNFTF stock can currently be purchased for approximately $16.72.

What is Genfit's official website?

The official website for Genfit is http://www.genfit.com/.

How can I contact Genfit?

The company can be reached via phone at 33 3 20 16 40 00.


MarketBeat Community Rating for Genfit (OTCMKTS GNFTF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Genfit and other stocks. Vote "Outperform" if you believe GNFTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNFTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: What is a back-end load?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel